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INTRODUCTION
Cervical carcinoma is the second most common
form of cancer and one of the most important causes
of death among women around the world [1]. Despite
numerous studies, treatment of cervical cancer has
remained a considerable problem, especially in devel
oping countries [2]. Human papilloma virus (HPV) is
the major cause of cervical cancer. More than 150
kinds of papilloma virus biotypes have been known
which are divided into genotypes of low, intermediate
and high risks based on the ability to induce oncogen
esis [3–5]. Despite conventional treatments like cryo
surgery, radiation and chemotherapy, a considerable
percent of patients continues to die from this disease
[6]. There is therefore a need for development of novel
treatment strategies [7, 8]. Several antiviral and
immunomodulatory agents were evaluated for treat
ment of HPVassociated cervical tumors [9]. Using
the immune system to fight cancer is the basis of bio
logical treatment methods. Nowadays, interferons
(IFNs) are used with chemotherapy in biological
treatments in order to strengthen the immune system.
Furthermore, several biological functions of IFNs,
including enhancement of the immune response by
activating certain immune cells such as natural killer
cells and dendritic cells, the antiangiogenic and
proapoptotic effects, make them suitable candidates
for anticancer therapy [10–12].
On the one hand, the HPV16 protein E7 was
shown to sensitize malignant cells to IFNα apopto
sis. On the other hand, IFNs, such as IFNα, IFNβ,
and IFNγ, suppress the E6 and E7 gene transcripts in
certain carcinoma cell lines [13]. The modulatory
effect of IFNs on papilloma tumor cells designated
them as promising therapeutic agents along with other
strategies for HPV tumors [14]. Among the different
types of IFNs, IFNα is the most widely used in spite
of the adverse effects induced, namely: nervous system
disorders, myelosuppression, flulike symptoms such
as tremble, fever, muscular aches, weakness, loosing
appetite, nausea, diarrhea and vomiting that limit its
application in clinical stages [10]. During recent years,
a new member of the IFN family named interferon
type III, or IFNλ, which was identified from the
human genomic sequence was classified as a member
of the cytokine type 2 family [15, 16]. This IFN dis
played antiviral and antitumor features [17–23]. Sato
et al. [21] demonstrated the antitumor effect of IFNλ in
the murine B16 melanoma and Colon 26 tumors.
They showed that NK cells were critical for IFNλ
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mediated tumor growth inhibition in vivo. The overex
pression of IFNλ in B16 cells induced cell surface
MHC class I and Fas (CD95) expression and more
over, markedly increased caspase3/7 activity con
comitant with cell cycle arrest and apoptosis [21].
IFNλ has similar signaling to that of IFNα [24–26].
Because of the limited number of receptors and caus
ing naturally less harm, the IFNα is considered as a
promising agent for cancer therapy [10, 26–28]. Here,
the antitumor activity of IFNλ3 was compared with
that of IFNα in papilloma tumors in a mouse model.
EXPERIMENTAL
Plasmids. The eukaryotic expression vector of
murine IFNλ3 (mIFNλ3) was kindly provided as a
gift from Dr. Sergio Kotenko [27], and the expression
vector of murine IFNα1 (mIFNα1) was dedicated
by Dr. Stefano Indraccolo [29]. The expression of both
IFNs in eukaryotic cells was confirmed by respective
researchers. To confirm the integrity of the vectors,
enzyme digestion with XbaI and BamH I of the pCMV
mIFNα1 plasmid and EcoRI and KpnI of the pEF
mIFNλ3 plasmid was performed. For plasmid injec
tions into mice, the plasmids were extracted using the
plasmid DNA purification kit (Intron Biotechnology,
Korea).
Cells. The TC1 cell line which expresses the HPV
16E7 and E6 oncoproteins, was used to create tumors
in the mouse animal model [30, 31]. The TC1 cells
were cultured in DMEM containing 5% of FBS
medium. The amount of 1 × 106 cells of the third pas
sage were injected into each mouse. The erythroleuke
mic cell line K562 was maintained in RPMI1600 and
used as target cells for the NK cell assay.
Animal study. Female C57BL/6 mice (5 weeks old)
were purchased from the Pasteur Institute of Iran. The
mice were housed for one week before starting the
experiment, and maintained in a good condition. All
experiments were done according to the Animal Care
and Use Protocol of Tarbiat Modares University. To
create tumors, 1 × 106 cells were injected to the left or
right flank of each mouse. Two weeks after the TC1
injection, when the size of tumors reached about 5 mm,
the randomized groups of 5 animals received 3 intratu
moral injections at 14day intervals as described in the
table.
The weight of the mice and the size of the tumors
were recorded carefully at each step of the experiment.
NK cell cytotoxicity assay. The lytic activity of NK
cells was assayed against the K562 cell line, as a highly
sensitive target for the NK cells [32]. Fourteen days
after the last injection, spleens were aseptically
removed and homogenized in complete RPMI1600
medium. The viability of splenocytes was determined
by trypan blue (0.4% w/v) exclusion, and the cells
were used as effector ones.
The K562 target cells were distributed into a 96well
plate (2 × 105 cells/well) in 50 μL of RPMI1600 with
1% serum. The effector cells were added to the target
cells at ratios of 25 : 1, 50 : 1 and 100 : 1 for a standard
lactate dehydrogenase (LDH) release assay. Wells con
taining 50 μL of K562 cells plus 50 μL of medium with
1% serum served as the “low” control (lC), with less
LDH release, while the “high” control (hC) con
tained 50 μL of K562 cells plus 50 μL of medium with
1% serum with lysis solution (which was added at the
end of the experiment). In the control well with the
effector cells (efC), 50 μL of the medium with 1%
serum plus 50 μL of spleen cells (the highest density
was used) were poured. All experiments were per
formed in triplicate.
The plates were incubated for 6 to 8 h at 37°С with
90% humidity and 5% СО2. Then 100 μL of a freshly
prepared reaction mixture (LDH Cytotoxicity Detec
tion Kit Plus, Roche, Germany) were added to each
well and incubated for 30 min in the dark. Finally, by
adding 50 μL of the stopsolution, the reaction was
stopped, and optical density was read at the wave
length of 492 nm (A492). The percentage of cytotoxic
ity was calculated with the following formula:
Percent Specific Release (%) 
= 100 × (Aef – Atar ⎯ AefC)/(AhC – AlC), 
where index A is A492 value for for effector (ef), target
(tar) cells and control cells (see above). The median
value for each triplicate was used for the calculations
of the cytotoxicity value.
Apoptosis assay. DNA fragmentation was deter
mined by using the In Situ Cell Death Detection kit
(Roche, Germany) according to the manufacturer’s
Diffferently treated groups of mice and injection protocol
Group Material injected The number of mice
Injection dose, 
μg/mL
Interval between 
injections, days
The number 
of injections
Control PBS 5 100 14 3
Testifier pcDNA3.1 5 100 14 3
IFNλ pEFmIFNλ3 5 100 14 3
IFNα pCMV mIFNα1 5 100 14 3
IFNα/λ pEFmIFNλ3 + pCMV mIFNα1 5 50 + 50 14 3
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protocol on deparaffinized tumor sections, and then
the samples were counter stained with hematoxylin
and eosin (H&E). The total number of cells in a given
area was determined by using DAPI staining. The apo
ptotic index was determined as the number of TUNEL
positive stained cells divided by the total cell number.
Three different sections from the center of the tumor
were considered for each sample.
Statistical analysis. Data obtained from the size of
tumor, NK cell cytotoxicity, apoptosis assay, body
weight and survival time were analyzed by oneway
ANOVA followed by SPSS software version 19. Values
of p < 0.05 were considered to be significant.
RESULTS
Measuring the Size of the Tumor
The average size of tumors on the first day of IFN
injection was 5 mm. Two weeks after the last injection
the sizes of the tumors were measured using a digital
caliper (Fig. 1). According to the accomplished calcu
lations, the average size of tumors in the control
groups of PBS or empty vector was not statistically dif
ferent. The mice received IFNλ had a significantly
smaller tumor sizes as compared to the controls (Fig. 1).
The injection of IFNα as well as the combined treat
ment with IFNα and IFNλ resulted in a reduction
in tumor size as compared to the IFNλ group (Fig. 1).
IFN Injection Increased the NK Cell Cytotoxicity
To verify that interferon therapy resulted in an
increased cytotoxic potential of NK cells, the splenic
cells isolated from treated mice were cocultured with
K562 target cells at different effector/target ratios.
These cells have a low MHC expression, which makes
them sensitive to NK cell killing. Figure 2 shows that
NK cells from control mice were unable to efficiently
lyse the target cells. In contrast, target cells were effi
ciently killed by NK cells from IFNα and IFNλ
treated mice. These data indicate that IFN treatment
strongly improves NK cell cytotoxicity in vitro. Fur
thermore, the mice injected with a combination of
IFNα and IFNλ showed a significantly higher spe
cific lysis compared to those of treated with IFNλ
alone (p < 0.05)
IFNInduced Apoptosis in Tumors
Cell apoptosis was measured by the TUNEL assay
using the In Situ Cell Death Detection kit 14 days after
the last injection. The results revealed the existence of
apoptotic cells in IFNλ, IFNα and IFNλ/α groups
what indicates the induction of apoptosis in tumors
upon IFN therapy (Fig. 3).
Apoptosis was quantified by determining the per
centage of biotinylateddUTP (bdUTP)positive cells
in a minimum of 1000 tumor cells counted in 10 fields
of 3 different sections from the center of the each
tumor (Fig. 4).
Body Weight and Survival Time
The time of survival was recorded for 7 days after
the last injection. Because of the large size of tumors in
the 12th weeks of the injection, the both control
groups, received PBS and PCDNA3.1+, were scari
fied. In IFNα group in the 11th week, 48 h after
injecting the second portion, 1 mouse died that was
possibly because of the side effect of IFNα. In IFNλ
and in IFNλ/α groups no death was observed
through 16 weeks. Mice body weights were recorded
carefully upon arrival to the lab in the 5th week of their
life, at the beginning of the experiment (6th week) and
2 weeks after the first injection (8th week) and also
7 days after the last injection. Naturally, average weight
of female C57BL/6 is between 16.9 to 20.7 g at 5 to
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Fig. 1. The mean tumor size 14 days after the last injection.
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Fig. 2. Cytotoxicity of NK cells. The cytotoxic capacity of
splenic NK cells derived from treated mice was signifi
cantly higher than that for the control groups (p < 0.05).
Data on the cytotoxicity induced by different treatments
are presented as mean ± SD calculated from 3 experi
ments.
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12 weeks [33] The average weight of animals in each
group at different time points was shown in Fig. 5.
DISCUSSION
As the new member of the cytokine type 3 family,
INFλ, was shown to have antiviral, antitumor and
immune regulatory activities [17, 28, 34]. IFNλ and
IFNα activate an identical group of genes. The
restricted amount of receptors of type III IFNs as
compared to type I allows us to consider them as pos
sible alternative agents for IFN therapy with fewer side
effects [10]. Depending on the tumor type, a great
variability was reported in sensitivity to IFN therapy,
especially in the case of INFλ. In the present study,
an antitumor activity of IFNλ alone or in combina
tion with IFNλ in TC1 papilloma tumor cells were
investigated in the C57BL/6 mice model. The TC1
cell line was immortalized with E6 and E7 of the pap
illoma virus. These oncoproteins were shown to make
cells sensitive to IFNinduced apoptosis. This prop
erty may depend on the activation of proapoptotic Bak
that is down regulated in E6 and E7 transfected cells
[13, 14]. It was reported that the TC1 cells originated
from C57BL/6 lungs express the IFNλ3 receptor
[35, 36].
In this study, the induction of apoptosis upon IFN
administration was shown. The chosen sections from
the center of the tumors with uniform cells partly con
firmed to cause apoptosis of tumor cells and not of
infiltrated lymphocytes which are usually localized
around blood vessels. Our findings are in accordance
with the data reported by Sato at al. [21] on IFNλ
induced apoptosis in murine B16 melanoma and
Colon26 cancer cells transduced with mouse IFNλ.
As achieved in previous studies, type III IFNs
improved the therapeutic efficacy of IFNα. In our
study, the combined administration of IFNλ and
IFNα displayed higher apoptotic death levels and
effective inhibitory action on tumor growth than indi
vidual IFNs. This regiment reduces the dose and side
effects of IFNλ administration [37, 38]. Although,
IFNα alone also showed a dramatic effect on tumor
size reduction and apoptosis induction in comparison
(a) (b)
(c) (d) (e)
Fig. 3. Tunnel test in tumor sections of mice from different groups: control (a), testifier (b), IFNλ (c), IFNα (d), and IFNλ/α (e).
The sections were stained with florescence (up) or DAB (bottom) conjugated antibodies. (The color variant is presented in the
Supplement to the article, see site www. molecbio.com.)
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with the control group, IFNα therapy was more
effective in these issues but the death of a mouse in this
group may be regarded as a side effect of IFNα
administration.
In addition to the direct apoptosis of tumor cells,
IFNs can elicit antitumor activity through the induc
tion of the immune response. It was proved that NK
cells are the most important cells mediating in vivo
antitumor activity of IFNλ [21]. IFNλ stimulates
and enhances the number and cytotoxic activity of NK
cells [21, 39]. Similarly, using the NK cell cytotoxicity
assay we demonstrated that the antitumor activity
induced by IFNλ was mediated by NK cells. All three
groups, which received IFN alone or in combination
showed statistically significant differences in NK cells
cytotoxicity as compared with the control groups and
more interestingly, in the IFNs combined group the
highest NK cells activity was detected. In summary,
this study revealed that IFNα has an antitumor activ
ity against the papilloma cervical cancer model
through induction of apoptosis and enhancement of
the NK cells activity. The combination of IFNα with
IFNλ showed a greater therapeutic effect and thus
may be considered as an alternative to IFNλ immu
notherapy in the treatment of papilloma tumors. At
present, IFNα is being investigated to be used for
curing some maladies such as hepatitis C [40], but
there is still very limited amount of data on the prop
erties IFNλ what demands more studies to evaluate
its potential as a remedial agent in the treatment of
tumors. The use of new agents in clinical phases needs
more investigations on its effects, route of administra
tion and application of a more safe form of the drug.
REFERENCES
1. de Weerd N.A., Samarajiwa S.A., Hertzog P.J. 2007.
Type I interferon receptors: Biochemistry and biologi
cal functions. J. Biol. Chem. 282, 20053–20057.
2. TjalmaW.A., van Waes T.R., van den Eeden L.E.,
Bogers J.J. 2005. Role of human papillomavirus in the
carcinogenesis of squamous cell carcinoma and adeno
carcinoma of the cervix. Best Pract. Res. Clin. Obstet.
Gynaecol. 19, 469–483.
3. Carter J.R., Ding Z., Rose B.R. 2011. HPV infection
and cervical disease: A review. Aust. N. Z. J. Obstet.
Gynaecol. 51, 103–108.
4. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L.,
Saraiya M., Bray F., Ferlay J. 2011. Worldwide burden
of cervical cancer in 2008. Ann. Oncol. 22, 2675–2686.
5. Anorlu R.I. 2008. Cervical cancer: The subSaharan
African perspective. Reprod. Health Matters. 16, 41–49.
6. Monk B.J., Mas Lopez L., Zarba J.J., Oaknin A.,
Tarpin C., Termrungruanglert W., Alber J. A., Ding J.,
Stutts M.W., Pandite L.N. 2010. Phase II, ppenlabel
study of pazopanib or lapatinib monotherapy compared
with pazopanib plus lapatinib combination therapy in
patients with advanced and recurrent cervical cancer.
J. Clin. Oncol. 28, 3562–3566.
7. Michel N., Öhlschläger P., Osen W., Freyschmidt E.J.,
Guthöhrlein H., Kaufmann A.M., Müller M., Giss
mann L. 2002. T cell response to human papillomavirus
16 E7 in mice: Comparison of Cr release assay, intrac
ellular IFNγ production, ELISPOT and tetramer
staining. Intervirology. 45, 290–299.
8. Leachman S.A., Shylankevich M., Slade M.D., Levine D.,
Sundaram R. K., Xiao W., Bryan M., Zelterman D.,
Tiegelaar R.E., Brandsma J.L. 2002. Ubiquitinfused
and/or multiple early genes from cottontail rabbit pap
illomavirus as DNA vaccines. J. Virol. 76, 7616–7624.
9. Lin C.T., Wang C.N., Lai C.H. 2013. Immunotherapy
for advanced or relapsed cervical cancer. Gynecol. Mini.
Invas. Ther. 2, 3–7.
10. Lasfar A., Abushahba W., Balan M., Cohen Solal K.A.
2011. Interferon lambda: A new sword in cancer immu
notherapy. Clin. Dev. Immunol. 2011, 349575.
11. Takaoka A., Hayakawa S., Yanai H., Stoiber D.,
Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T.,
Honda K., Taniguchi T. 2003. Integration of inter
feronα/β signalling to p53 responses in tumour sup
pression and antiviral defence. Nature. 424, 516–523.
A
ve
ra
ge
 w
ei
gh
t,
 g
30
25
20
15
10
6 8 12
Age of mice, weeks
Control
Testifier
IFNλ
IFNα
IFNλ/α
5
Fig. 5. The average body weight of tumorbearing mice at
different time points. The weight differences among inter
feron treated and control groups are partly due to the
weight of the tumors.
A
po
pt
os
is
 in
 t
um
or
s,
 %
80
60
40
20
0
Control IFNλ IFNα IFNλ/α
and Testifier
Fig. 4. IFN induced apoptosis in tumors. The highest level
of apoptosis was detected in IFNλ/α group and the lowest
one was in control and testifier groups.
MOLECULAR BIOLOGY  Vol. 49  No. 5  2015
ANTITUMOR EFFECT OF mIFNλ3 IN C57BL/6 MICE MODEL 699
12. Le Bon A., Tough D.F. 2002. Links between innate and
adaptive immunity via type I interferon. Curr. Opin.
Immunol. 14, 432–436.
13. Thyrell L., Sangfelt O., Zhivotovsky B., Pokrovskaja K.,
Wang Y., Einhorn S., Grandér D. 2005.The HPV16 E7
oncogene sensitizes malignant cells to IFNalpha
induced apoptosis. J. Interferon Cytokine Res. 25, 63–72.
14. Kim K.Y., BlattL., Taylor M.W. 2000. The effects of
interferon on the expression of human papillomavirus
oncogenes. J. Gen. Virol. 81, 695–700.
15. Sheppard P., Kindsvogel W., Xu W., Henderson K.,
Schlutsmeyer S., Whitmore T.E., Kuestner R.,Garri
gues U., Birks C., Roraback J., Ostrander C., Dong D.,
Shin J., Presnell S., Fox B., et al. 2003. IL28, IL29
and their class II cytokine receptor IL28R. Nat.
Immunol. 4, 63–68.
16. Kotenko S.V., Gallagher G., Baurin V.V., Lewis Antes A.,
Shen M., Shah N.K., Langer J.A., Sheikh F., Dicken
sheets H., Donnelly R.P. 2003. IFNlambdas mediate
antiviral protection through a distinct class II cytokine
receptor complex. Nat. Immunol. 4, 69–77.
17. Kotenko S.V. 2011. IFNλs. Curr. Opin. Immunol. 23,
583–590.
18. Li M., Chen Y., Huang T., Liu Y., He S. 2006. Produc
tion, characterization, and applications of two novel mono
clonal antibodies against human interleukin28A. Tissue
Antigens. 68, 477–482.
19. Numasaki M., Tagawa M., Iwata F., Suzuki T., Naka
mura A., Okada M., Iwakura Y., Aiba S., Yamaya M.
2007. IL28 elicits antitumor responses against murine
fibrosarcoma. J. Immunol. 178, 5086–5098.
20. Dumoutier L., Tounsi A., Michiels T., Sommereyns C.,
Kotenko S.V., Renauld J.C. 2004. Role of the interleu
kin (IL)28 receptor tyrosine residues for antiviral and
antiproliferative activity of IL29/Interferonλ1: Simi
larities with type I interferon signaling. J. Biol. Chem.
279, 32269–32274.
21. Sato A., Ohtsuki M., Hata M., Kobayashi E.,
Murakami T. 2006. Antitumor activity of IFNλ in
murine tumor models. J. Immunol. 176, 7686–7694.
22. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T.,
Otte J.M., Diebold J., Diepolder H., Adler B., Auern
hammer C.J., Göke B., Dambacher J. 2005. IL28A
and IL29 mediate antiproliferative and antiviral sig
nals in intestinal epithelial cells and murine CMV
infection increases colonic IL28A expression. Am. J.
Physiol. Gastrointest. Liver Physiol. 289, G960–G968.
23. Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L.
2005. Murine interferon lambdas (type III interferons)
exhibit potent antiviral activity in vivo in a poxvirus
infection model. J. Gen. Virol. 86, 1589–1596.
24. Maher S.G., Sheikh F., Scarzello A.J., Romero
Weaver A.L., Baker D.P., Donnelly R.P., Gamero A.M.
2008. IFNα and IFNλ differ in their antiproliferative
effects and duration of JAK/STAT signaling activity.
Cancer Biol. Ther. 7, 1109–1115.
25. Zitzmann K., Brand S., Baehs S., Göke B., Meinecke J.,
Spöttl G., Meyer H., Auernhammer C.J. 2006. Novel
interferonλs induce antiproliferative effects in neu
roendocrine tumor cells. Biochem. Biophys. Res. Com
mun. 344, 1334–1341.
26. Tagawa M., Kawamura K., Li Q., Tada Y., Hiroshima K.,
Shimada H. 2011. A possible anticancer agent, type III
interferon, activates cell death pathways and produces
antitumor effects. Clin. Dev. Immunol. 2011, 6.
27. Lasfar A., Lewis Antes A., Smirnov S.V., Anantha S.,
Abushahba W., Tian B., Reuhl K., Dickensheets H.,
Sheikh F., Donnelly R.P., Raveche E., Kotenko S.V.
2006. Characterization of themouse IFNλ ligand
receptor system: IFNλs exhibit antitumor activity
against B16 melanoma. Cancer Res. 66, 4468–4477.
28. Li M., Liu X., Zhou Y., Su S.B. 2009. Interferonλs:
The modulators of antivirus, antitumor, and immune
responses. J. Leukoc. Biol. 86, 23–32.
29. Calabrò M.L., Gasperini P., Di Gangi I. M., Indrac
colo S., Barbierato M., Amadori A., Chieco Bianchi L.
2009. Antineoplastic activity of lentiviral vectors
expressing interferonα in a preclinical model of pri
mary effusion lymphoma. Blood. 113, 4525–4533.
30. Li J., Sun Y., Garen A. 2002. Immunization and immu
notherapy for cancers involving infection by a human
papillomavirus in a mouse model. Proc. Natl. Acad. Sci.
U. S. A. 99, 16232–16236.
31. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M.,
Wu T.C.1998. Antigenspecific immunotherapy for
murine lung metastatic tumors expressing human pap
illomavirus type 16 E7 oncoprotein. Int. J. Cancer. 78,
41–45.
32. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J.,
Lockey T., Eldridge P., Leung W.H., Campana D. 2009.
Expansion of highly cytotoxic human natural killer cells
for cancer cell therapy. Cancer Res. 69, 4010–4017.
33. Body weight information, JAX mice strain C57BL/6J.
2014. The Jackson Laboratory. http://jaxmice.jax.org/
support/weight/000664.html.
34. Abushahba W., Balan M., Castaneda I., Yuan Y., Reuhl K.,
Raveche E., Torre A., Lasfar A., KotenkoS. 2010. Anti
tumor activity of type I and type III interferons in BNL
hepatoma model. Cancer Immunol. Immunother. 59,
1059–1071.
35. Ank N., West H., Bartholdy C., Eriksson K., Thom
sen A.R., Paludan S.R. 2006. Lambda interferon
(IFNλ), a type III IFN, is induced by viruses and
IFNs and displays potent antiviral activity against select
virus infections in vivo. J. Virol. 80, 4501–4509.
36. Mordstein M., Neugebauer E., Ditt V., Jessen B.,
Rieger T., Falcone V., Sorgeloos F., Ehl S., Mayer D.,
Kochs G., Schwemmle M., Günther S., Drosten C.,
Michiels T., Staeheli P. 2010. Lambda interferon ren
ders epithelial cells of the respiratory and gastrointestinal
tracts resistant to viral infections. J. Virol. 84, 5670–5677.
37. Cascinelli N., Belli F., MacKie R.M., Santinami M.,
Bufalino R., Morabito A. 2001. Effect of longterm
adjuvant therapy with interferon alpha2a in patients
with regional node metastases from cutaneous mela
noma: A randomised trial. Lancet. 358, 866–869.
38. Kleeberg U.R., Suciu S., Bröcker E.B., Ruiter D.J.,
Chartier C., Liénard D., Marsden J., Schadendorf D.,
Eggermont A.M.M. 2004. Final results of the EORTC
18871/DKG 801 randomised phase III trial: rIFN
α2b versus rIFNγ versus ISCADOR M versus observa
tion after surgery in melanoma patients with either
highrisk primary (thickness >3 mm) or regional lymph
node metastasis. Eur. J. Cancer. 40, 390–402.
39. Eckl Dorna J. 2012. Editorial: Natural killer cellmedi
ated augmentation of autoantibody production?
J. Leukoc. Biol. 92, 695–697.
40. O’Brien T.R. 2009. Interferonalfa, interferonlambda
and hepatitis C. Nat. Genet. 41, 1048–1050.
